Alle Storys
Folgen
Keine Story von Girindus AG i.L. mehr verpassen.

Girindus AG i.L.

ots Ad hoc-Service: Girindus AG <DE0005880405> GIRINDUS SIGNS MEMORANDUM OF UNDERSTANDING TO ACQUIRE API DEVELOPMENT AND PILOT PLANT OF AVENTIS PHARMACEUTICALS IN CINCINNATI, OHIO, USA

Bergisch-Gladbach, Germany (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
Girindus AG and
Aventis Pharmaceuticals Inc. have signed a Memorandum of
Uunderstanding for the proposed Girindus acquisition of Aventis
Pharmaceuticals APIs (Active Pharmaceutical Ingredients) development,
radiochemistry and cGMP pilot manufacturing facilities in Cincinnati,
Ohio, by the end of 2000. The closing of the transaction is subject
to further due diligence by the parties and negotiation of definitive
agreements acceptable to the parties. Under the proposed acquisition,
Girindus will produce APIs at the Cincinnati facilities for Aventis
Pharmaceuticals during the next three years. Thereafter, Aventis
Pharmaceuticals will consider to develop a long-term outsourcing
partnership with Girindus.
The intended acquisition is a major milestone in the Girindus
expansion strategy to strengthen U.S. market presence. Girindus, with
global headquarters in Bensberg, Germany, has been serving U.S.
customers since 1986 through its sales and marketing office in Tampa,
Florida. The acquisition would add advanced process R&D and
sophisticated production capabilities to Girindus operations in the
U.S., the worlds largest biopharmaceutical market.
The combination of Girindus U.S. facilities with its European
Scale-Up and production center at Halle-Kuensebeck, Westphalia,
Germany, can greatly enhance the companys overall process development
and significantly increase production capabilities for a broader
portfolio of API projects. Fritz Link, CEO of Girindus: "The proposed
acquisition of the Cincinnati facilities will strengthen Girindus
position as a One-Stop- Shop for process development, radiolabeling,
Scale-Up and production of APIs for preclinical and clinical studies
as well as commercialization".
The fully equipped 50,000 square-foot (  5,000 square meters)
development and pilot facilities in Cincinnati are currently staffed
with more than 20 more than 20 experienced Aventis development
scientists. The facilities have capacity for about 45 process
associates. Approximately 5.5 acres ( 22,000 square meters)
surrounding the building site offer additional space for future
expansion.
The Cincinnati facilities currently provide process development
services and APIs for preclinical and early clinical studies of
Aventis Pharmaceuticals U.S. Drug Innovation and Approval (DI&A)
research and development unit, based in Bridgewater, New Jersey.
Aventis Pharmaceuticals is concentrating its new chemical development
and pilot laboratories in Bridgewater with completion expected in
2002.
Aventis S.A. (NYSE: AVE) is one of the world's leading life
science companies, focused on two core business areas -
pharmaceuticals and agriculture. With global corporate headquarters
in Strasbourg, France, Aventis employs around 90,000 people in 120
countries and recorded pro forma sales in 1998 of euro 21 billion (US
$21.65 billion). Aventis was launched in December 1999 through the
merger of Hoechst AG and Rhone-Poulenc S.A. Aventis Pharma AG is the
pharmaceutical company of Aventis S.A. Aventis Pharma is dedicated to
treating and preventing human disease through the discovery,
development, manufacture and sale of innovative pharmaceutical
products aimed at satisfying unmet medical needs. Aventis Pharma
focuses on important therapeutic areas such as cardiology, oncology,
infectious diseases, arthritis, allergies and respiratory disorders,
diabetes and the central nervous system disorders. Aventis Pharma has
its corporate headquarters in Frankfurt, Germany. Aventis Pharma also
encompasses Aventis Pasteur, a world leader in vaccines based in
Lyon, France, and Aventis Behring, a world leader in therapeutic
proteins headquartered in King of Prussia, Pennsylvania, USA. For
more information, please visit www.aventis.com
Girindus AG (Neuer Mark, Frankfurt, Germany: GIR, WKN 588040) isa
a unique technology-driven company offering the biopharmaceutical
industry comprehensive skills including process R&D, c-GMP compliant
SScale-Up and pProduction facilities, as well as regulatory
assistance. The Girindus seScale-Up and production center at
Halle-Kuensebeck in Westphalia, Germany, operations has already been
successfully inspected by the FDA several times. Current available
technologies include enzymatic reactions and chemical organic
chemistry.
For more information please visit www.girindus.com

Contact:

Girindus AG Barbara Scharte, Investor Relations Manager
bscharte@girindus.com Phone: ++49 2204 926 934

End
Internet: http://recherche.newsaktuell.de

Original-Content von: Girindus AG i.L., übermittelt durch news aktuell

Weitere Storys: Girindus AG i.L.
Weitere Storys: Girindus AG i.L.
  • 24.08.2000 – 08:36

    ots Ad hoc-Service: Girindus AG <DE0005880405>

    Bergisch-Gladbach (ots Ad hoc-Service) - . Sales and earnings according to plan . Reorientation accelerated . High investments in R&D, technologies and personnel . 6 new APIs: just the beginning Sales and earnings of Girindus AG developed according to plan in the first six months of FY 2000. At DEM 12.3 million, first-half sales reached almost exactly the targeted DEM 12.4 million. Earnings per ...